Immuron Limited (IMRN)

Market Cap	13.15M
Revenue (ttm)	1.24M
Net Income (ttm)	-2.61M
Shares Out	5.69M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,476
Open	2.06
Previous Close	2.10
Day's Range	2.05 - 2.08
52-Week Range	1.39 - 3.21
Beta	1.24
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 19, 2023

About IMRN

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: IMRN

Financial Performance

In 2023, Immuron's revenue was 1.80 million, an increase of 135.85% compared to the previous year's 765,193. Losses were -3.79 million, 32.7% more than in 2022.

Financial numbers in AUD